Results suggest a highly potent next-generation treatment that could offer greater efficacy with less frequent dosing SRP-5051 dosed monthly at 30 mg/kg delivered mean exon skipping of 10.79% and mean dystrophin […]
Join us for a presentation on the clinical development process behind approved therapies and the importance of dose and administration of corticosteroids by Dr. Emma Ciafaloni. This presentation will be […]
Today, CureDuchenne Ventures is pleased to share that we made a research investment into Code BioTherapeutics and their next-generation gene therapy platform. This is a promising technology aimed at overcoming […]
Webinar Information PepGen presents an overview of its enhanced delivery oligonucleotide platform and how this innovative platform technology is being applied to create a transformative exon skipping therapy. James McArthur, […]
Built by the community, for the community, the DuchenneXchange has offered a secure place to inform, inspire and empower those living with Duchenne since its inception in 2018. By offering […]
CureDuchenne continued funding a robust Duchenne drug development pipeline with a new investment in Entrada Therapeutics as part of their latest financing from a group of investors. Entrada Therapeutics’ promising […]
This webinar covers the following topics: Understanding the Clinical Trial Process Managing Expectations Featured Speakers: Ana Christensen, MPH – TRiNDS and Italfarmaco Leslie Porter – Family, Duchenne Advocate Michael Kelly, […]
NEWPORT BEACH, Calif., Mar. 18, 2021 – CureDuchenne, a leading global nonprofit focused on finding and funding a cure for Duchenne muscular dystrophy, announces a webinar to continue educating the Duchenne community about […]
Enhancing Muscle Delivery of ASOs to treat Duchenne Dyne is excited to present an overview of their FORCETM platform and DMD drug development program to the Duchenne community and then […]
